clotidal 10 mg/g krem dopochwowy
us pharmacia sp. z o.o. - clotrimazolum - krem dopochwowy - 10 mg/g
aporami 1,25 mg tabletki
aurovitas pharma polska sp. z o.o. - ramiprilum - tabletki - 1,25 mg
aporami 2,5 mg tabletki
aurovitas pharma polska sp. z o.o. - ramiprilum - tabletki - 2,5 mg
aporami 10 mg tabletki
aurovitas pharma polska sp. z o.o. - ramiprilum - tabletki - 10 mg
toralis 10 mg + 5 mg tabletki
aflofarm farmacja polska sp. z o.o. - lisinoprilum + torasemidum - tabletki - 10 mg + 5 mg
toralis 10 mg + 10 mg tabletki
aflofarm farmacja polska sp. z o.o. - lisinoprilum + torasemidum - tabletki - 10 mg + 10 mg
toralis 20 mg + 5 mg tabletki
aflofarm farmacja polska sp. z o.o. - lisinoprilum + torasemidum - tabletki - 20 mg + 5 mg
toralis 20 mg + 10 mg tabletki
aflofarm farmacja polska sp. z o.o. - lisinoprilum + torasemidum - tabletki - 20 mg + 10 mg
aporami 5 mg tabletki
aurovitas pharma polska sp. z o.o. - ramiprilum - tabletki - 5 mg
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - Środki przeciwnowotworowe - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.